Han Kiwon, Commissioner, Invest Korea
The head of the government agency charged with attracting and promoting FDI in Korea discusses how the country has ideally positioned itself between China and western markets through a series…
Invest Korea (IK), Korea’s national investment promotion agency, was established within the Korea Trade-Investment Promotion Agency (KOTRA) with the sole purpose of supporting the entry and successful establishment of foreign business into Korea. With assistance extending to comprehensive post-establishment services, IK enables foreign corporations to maximize the benefits of the Korean investment environment to ensure their rapid settlement in Korea. The agency is committed to providing unmatched, comprehensive one-stop service that allows foreign investors to join many of the world’s most successful corporations who have selected Korea as an investment destination and been rewarded by high returns on the investment.
Contact Details
13, Heolleung-ro Seocho-gu,
Seoul
Republic of Korea (137-749)
Tel. 82-1600-7119
E-mail ikonline@kotra.or.kr
The head of the government agency charged with attracting and promoting FDI in Korea discusses how the country has ideally positioned itself between China and western markets through a series…
Could you please give a brief presentation of Invest Korea to our readers? Invest Korea is the national investment promotion agency, responsible for attracting FDI into Korea. We have existed…
National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of…
Seung-Kyou Lee, vice-president of Korea Bio gives his assessment on the current landscape for biotech firms in Korea. He also discusses Korea Bio’s programme to create a further 1000 biotech…
Young-Whan Park, president of National OncoVenture, discusses their programme to support oncology drug development in South Korea, with a view to discovering and producing a globally competitive, Korean-made oncology medicine.…
Christoph Heider, president of the European Chamber of Commerce in Korea (ECCK), discusses the organization, the need for the modernization of the Europe-South Korea Free Trade Agreement, and the future…
Southeast Asia’s notoriously strict anti-cannabis laws could be set to relax dramatically as South Korea becomes the first country in the region to legalise cannabis for medicinal use. This…
Sunyoung Kim, CEO and founder of ViroMed, reveals his strategy for conquering the US market and the feasibility of his ambitions for ViroMed to become the biotech company with the…
In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into biologics, and how Samsung Biologics has rapidly become one of…
Professor Dukgeun Ahn of Seoul National University, trade policy advisor to the Ministry of Health offers his insights into the current policies towards the healthcare industry in Korea, and the…
South Korea’s proposed Moon Jae-In Care has been subject to both praise and protest this year. President Moon Jae-in’s plan dubbed “Moon Care” will be implemented in stages throughout 2022…
Jongmoon Kim, CEO of ToolGen discusses the potential for their CRISPR technology to revolutionize not only therapy for genetic illnesses, but also agriculture. Kim explains his move from information technology…
JungTae Park, senior managing director of KoBIA (Korea Biomedicine Industry Association), describes the achievements of the association as a bridge between industry and government. He also highlights the potential of…
Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu…
See our Cookie Privacy Policy Here
